Ryo Tsunashima

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Positive Breast Cancer

Gas Chromatography

Machine Learning

Top Venues

Breast cancer (Tokyo, Japan)

This page only lists publications with an associated author ORCID identifier.

Publications

Sae Kitano, Ryo Tsunashima, Chikage Kato, Akira Watanabe, Yoshiaki Sota, Saya Matsumoto, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer. Breast cancer (Tokyo, Japan) (2024)
Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
Investigation of recurrence prediction ability of EndoPredict ® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict ® from microarray data from fresh-frozen to FFPE tissues. Breast cancer (Tokyo, Japan) 31 (4) (2024)
Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
Investigation of recurrence prediction ability of EndoPredict ® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict ® from microarray data from fresh-frozen to FFPE tissues. Breast cancer (Tokyo, Japan) (2024)
Sae Kitano, Ryo Tsunashima, Chikage Kato, Akira Watanabe, Yoshiaki Sota, Saya Matsumoto, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
Investigation of recurrence prediction ability of EndoPredict ® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict ® from microarray data from fresh-frozen to FFPE tissues. Breast cancer (Tokyo, Japan) 31 (4) (2024)